Patrys Limited Advances with Promising Deoxymab Data
Company Announcements

Patrys Limited Advances with Promising Deoxymab Data

Patrys Limited (AU:PAB) has released an update.

Patrys Limited, a developer of therapeutic antibodies, announced the successful completion of a GMP production run and promising preclinical data suggesting their deoxymabs may treat autoimmune diseases like vasculitis. This advancement showcases the potential for the company’s technology to address new therapeutic areas. Additionally, Patrys reported a healthy financial position with $3 million in cash and short-term investments as of March 31, 2024.

For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskPatrys Limited Shifts Focus to Promising Antibody PAT-DX3
TipRanks Australian Auto-Generated NewsdeskPatrys Limited Announces Virtual AGM for 2024
TipRanks Australian Auto-Generated NewsdeskPatrys Limited Refocuses on Promising PAT-DX3 Antibody
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App